keyword
MENU ▼
Read by QxMD icon Read
search

finasterid

keyword
https://www.readbyqxmd.com/read/28416373/inhibition-effects-of-chlorogenic-acid-on-benign-prostatic-hyperplasia-in-mice
#1
Ya Huang, Huaguo Chen, Xin Zhou, Xingdong Wu, Enming Hu, Zhengmeng Jiang
This study aimed to evaluate the inhibitory effects and explore mechanisms of chlorogenic acid against testosterone-induced benign prostatic hyperplasia (BPH) in mice. Benign prostatic hyperplasia model was induced in experimental groups by daily subcutaneous injections of testosterone propionate (7.5mg/kg/d) consecutively for 14 d. A total of 60 mice were randomly divided into six groups: (Group 1) normal control group, (Group 2) benign prostatic hyperplasia model control group, (Group 3) benign prostatic hyperplasia mice treated with finasteride at a dose of 1mg/kg, (Group 4) benign prostatic hyperplasia mice treated with chlorogenic acid at dose levels of 0...
April 14, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28408350/neuroactive-steroid-levels-and-psychiatric-and-andrological-features-in-post-finasteride-patients
#2
Roberto Cosimo Melcangi, Daniele Santi, Roberto Spezzano, Maria Grimoldi, Tommaso Tabacchi, Maria Letizia Fusco, Silvia Diviccaro, Silvia Giatti, Giuseppe Carrà, Donatella Caruso, Manuela Simoni, Guido Cavaletti
Recent reports show that, in patients treated with finasteride for male pattern hair loss, persistent side effects including sexual side effects, depression, anxiety and cognitive complaints may occur. We here explored the psychiatric and andrological features of patients affected by post-finasteride syndrome (PFS) and verified whether the cerebrospinal fluid (CSF) and plasma levels of neuroactive steroids (i.e., important regulators of nervous function) are modified. We found that eight out of sixteen PFS male patients considered suffered from a DSM-IV major depressive disorder (MDD)...
April 10, 2017: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/28407365/role-of-allopregnanolone-biosynthesis-in-acute-stress-induced-anxiety-like-behaviors-in-mice
#3
Kazumi Yoshizawa, Ayano Okumura, Kozue Nakashima, Tomoyo Sato, Tatsuya Higashi
The neurosteroid allopregnanolone (3α, 5α-tetra-hydroprogesterone: ALLO) elicits anxiolytic, anticonvulsant, and hypnotic anesthetic effects in vivo similar to those induced by other positive allosteric modulators of the GABAA receptor. Endogenous ALLO has been shown to be rapidly elevated in the brain by acute stress paradigms, such as immobilization, in animal models. The present study was designed to ascertain the role of neurosteroid biosynthesis in the anxiety-like behavior induced by immobilization stress...
April 13, 2017: Synapse
https://www.readbyqxmd.com/read/28396101/the-effectiveness-of-treatments-for-androgenetic-alopecia-a-systematic-review-and-meta-analysis
#4
REVIEW
Areej Adil, Marshall Godwin
BACKGROUND: Androgenetic alopecia, or male pattern hair loss, is a hair loss disorder mediated by dihydrotestosterone, the potent form of testosterone. Currently, minoxidil and finasteride are Food and Drug Administration (FDA)-approved, and HairMax LaserComb, which is FDA-cleared, are the only treatments recognized by the FDA as treatments of androgenetic alopecia. OBJECTIVE: This systematic review and meta-analysis assesses the efficacy of nonsurgical treatments of androgenetic alopecia in comparison to placebo for improving hair density, thickness, growth (defined by an increased anagen:telogen ratio), or subjective global assessments done by patients and investigators...
April 7, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28393993/-finasteride-adverse-effects-an-update
#5
Néstor Carreño-Orellana, Catherina Moll-Manzur, Juan Eduardo Carrasco-Zuber, Sergio Álvarez-Véliz, Daniela Berroeta-Mauriziano, Ninoska Porras-Kusmanic
Finasteride is a 5-α reductase inhibitor that is widely used in the management of benign prostate hyperplasia and male pattern hair loss. It is well known that these agents improve the quality of life in men suffering from these conditions. However, they are associated with some transient and even permanent adverse effects. The aim of this article is to clarify the controversies about the safety of finasteride by analyzing the evidence available in the literature.
December 2016: Revista Médica de Chile
https://www.readbyqxmd.com/read/28391389/combination-therapy-with-omega-3-fatty-acids-plus-tamsulocin-and-finasteride-in-the-treatment-of-men-with-lower-urinary-tract-symptoms-luts-and-benign-prostatic-hyperplasia-bph
#6
Alireza Ghadian, Mehran Rezaei
PURPOSE: Inflammation and Cyclooxygenase-2 (COX-2) as a part of it are common in BPH specimens and may play a role in the pathogenesis of the disease through cytokines that promote cell growth or lead to smooth muscle contraction. The aim of this study is to analyze whether combination therapy with omega-3 fatty acids, which have anti-inflammatory and COX-2 inhibitory effects, and tamsulocin plus finasteride offers an advantage compared to tamsulocin plus finasteride therapy in patients with BPH...
April 8, 2017: Inflammopharmacology
https://www.readbyqxmd.com/read/28385453/co-clinical-analysis-of-a-genetically-engineered-mouse-model-and-human-prostate-cancer-reveals-significance-of-nkx3-1-expression-for-response-to-5%C3%AE-reductase-inhibition
#7
Aditya Dutta, Sukanya Panja, Renu K Virk, Jaime Yeji Kim, Roseann Zott, Serge Cremers, David M Golombos, Deli Liu, Juan Miguel Mosquera, Elahe A Mostaghel, Christopher E Barbieri, Antonina Mitrofanova, Cory Abate-Shen
BACKGROUND: Although men on active surveillance for prostate cancer (PCa) may benefit from intervention with 5α-reductase inhibitors (5-ARIs), it has not been resolved whether 5-ARIs are effective for delaying disease progression and, if so, whether specific patients are more likely to benefit. OBJECTIVE: To identify molecular features predictive of patient response to 5-ARIs. DESIGN, SETTING, AND PARTICIPANTS: Nkx3.1 mutant mice, a model of early-stage PCa, were treated with the 5-ARI finasteride, and histopathological and molecular analyses were performed...
April 3, 2017: European Urology
https://www.readbyqxmd.com/read/28360960/clomiphene-citrate-rescue-of-spermatogenesis-in-men-with-infertility-while-remaining-on-finasteride-a-case-report
#8
Christopher Wu, Ellen Forbes, Keith Allen Jarvi
No abstract text is available yet for this article.
March 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28338531/hormonal-manipulation-with-finasteride-or-oral-contraception-does-not-influence-incidence-of-renal-cell-carcinoma
#9
Aashish Kabra, Jonathan Gelfond, Michael A Liss
Androgens have been suspected to be involved in the initiation of renal cell carcinoma because of a two-fold increased risk in men compared with women. To investigate the role of self-reported finasteride or oral contraceptive use in the Prostate, Lung, Colorectal, and Ovarian (PCLO) to determine whether the androgen receptor reduces renal cancer development. We query the PCLO trial for predictor variables from the baseline questionnaire and follow-up questionnaires enquiring medication use, specifically the use of 5-α reductase inhibitors (dutasteride or finasteride) and oral contraceptive therapy...
March 23, 2017: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/28338402/testosterone-plus-finasteride-prevents-bone-loss-without-prostate-growth-in-a-rodent-spinal-cord-injury-model
#10
Joshua F Yarrow, Ean G Phillips, Christine F Conover, Taylor E Bassett, Cong Chen, Tyler Teurlings, Andrea Vasconez, Jonathan Alerte, Hannah M Prock, Jessica M Jiron, Micah Flores, J Ignacio Aguirre, Stephen E Borst, Fan Ye
We have reported that testosterone-enanthate (TE) prevents the musculoskeletal decline occurring acutely after spinal cord injury (SCI), but results in a near doubling of prostate mass. Our purpose was to test the hypothesis that administration of TE plus finasteride (FIN, type II 5α-reductase inhibitor) would prevent the chronic musculoskeletal deficits in our rodent severe contusion SCI model, without inducing prostate enlargement. Forty-three 16-week old male Sprague-Dawley rats received: (1) SHAM surgery (T9 laminectomy), (2) severe (250 kdyne) contusion SCI, (3) SCI+TE (7...
March 24, 2017: Journal of Neurotrauma
https://www.readbyqxmd.com/read/28319231/association-of-suicidality-and-depression-with-5%C3%AE-reductase-inhibitors
#11
Blayne Welk, Eric McArthur, Michael Ordon, Kelly K Anderson, Jade Hayward, Stephanie Dixon
Importance: There have been concerns raised by patients and regulatory agencies regarding serious psychiatric adverse effects associated with 5α-reductase inhibitors. Objective: To determine if there is an increased risk of suicide, self-harm, or depression among older men starting a 5α-reductase inhibitor for prostatic enlargement. Design, Setting, and Participants: A population-based, retrospective, matched cohort study using linked administrative data for 93 197 men ages 66 years or older (median [IQR] age, 75 [70-80] years) in Ontario, Canada, who initiated a new prescription for a 5α-reductase inhibitor during the study period (2003 through 2013)...
March 20, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28317149/association-between-variants-in-genes-involved-in-the-immune-response-and-prostate-cancer-risk-in-men-randomized-to-the-finasteride-arm-in-the-prostate-cancer-prevention-trial
#12
Danyelle A Winchester, Cathee Till, Phyllis J Goodman, Catherine M Tangen, Regina M Santella, Teresa L Johnson-Pais, Robin J Leach, Jianfeng Xu, S Lilly Zheng, Ian M Thompson, M Scott Lucia, Scott M Lippman, Howard L Parnes, William B Isaacs, Angelo M De Marzo, Charles G Drake, Elizabeth A Platz
BACKGROUND: We reported that some, but not all single nucleotide polymorphisms (SNPs) in select immune response genes are associated with prostate cancer, but not individually with the prevalence of intraprostatic inflammation in the Prostate Cancer Prevention Trial (PCPT) placebo arm. Here, we investigated whether these same SNPs are associated with risk of lower- and higher-grade prostate cancer in men randomized to finasteride, and with prevalence of intraprostatic inflammation among controls...
June 2017: Prostate
https://www.readbyqxmd.com/read/28301260/cancer-targeting-potential-of-99m-tc-finasteride-in-experimental-model-of-prostate-carcinogenesis
#13
Gowsia Jan, Neelima D Passi, Devinder Kumar Dhawan, Vijayta Dani Chadha
This study aimed to radiolabel finasteride, a novel 5α-reductase inhibitor, to evaluate its cancer targeting potential in experimental model of prostate carcinogenesis. Finasteride was effectively radiolabeled with (99m)Tc and showed >90% labeling efficiency. The radiopharmaceutical was found to be stable up to 6 hours in rat serum at 37°C. The blood kinetics of the (99m)Tc-finasteride followed a biphasic release pattern, whereby fast-release phase was observed at 15 seconds and a slow-release phase was observed after 30 minutes of administration...
March 2017: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/28300347/assessing-finasteride-associated-sexual-dysfunction-using-the-faers-database
#14
A K Gupta, J Carviel, M A MacLeod, N Shear
BACKGROUND: Postmarketing reports suggest that finasteride causes sexual dysfunction despite a low incidence reported in clinical trials. Therefore, the extent of risk remains unknown. OBJECTIVE: To determine whether the risk of sexual dysfunction is higher among individuals treated with finasteride compared to a baseline risk for all other drugs using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database. METHODS: A case by non-case disproportionality approach was used whereby a reporting odds ratio (ROR) with 95% confidence interval (CI) was calculated...
March 16, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28294070/dutasteride-in-androgenetic-alopecia-an-update
#15
Tasleem Arif, Konchok Dorjay, Mohammad Adil, Marwa Sami
BACKGROUND: Androgenetic alopecia is a common condition characterized by thinning of scalp hair. Conversion of testosterone to dihydrotestosterone, a more potent androgen, by the enzyme 5-a-reductase is responsible for underlying pathogenesis. Dutasteride, a synthetic 4-azasteroid, is a selective and competitive inhibitor of both type-1 and type-2 isoenzymes of 5-alpha-reductase. Finasteride and minoxidil are the only approved drugs for androgenetic alopecia. Dutasteride has been demonstrated to be effective in several randomized, double-blind, placebo controlled trials in androgenetic alopecia...
March 10, 2017: Current Clinical Pharmacology
https://www.readbyqxmd.com/read/28289563/persistent-erectile-dysfunction-in-men-exposed-to-the-5%C3%AE-reductase-inhibitors-finasteride-or-dutasteride
#16
Tina Kiguradze, William H Temps, Paul R Yarnold, John Cashy, Robert E Brannigan, Beatrice Nardone, Giuseppe Micali, Dennis Paul West, Steven M Belknap
IMPORTANCE: Case reports describe persistent erectile dysfunction (PED) associated with exposure to 5α-reductase inhibitors (5α-RIs). Clinical trial reports and the manufacturers' full prescribing information (FPI) for finasteride and dutasteride state that risk of sexual adverse effects is not increased by longer duration of 5α-RI exposure and that sexual adverse effects of 5α-RIs resolve in men who discontinue exposure. OBJECTIVE: Our chief objective was to assess whether longer duration of 5α-RI exposure increases risk of PED, independent of age and other known risk factors...
2017: PeerJ
https://www.readbyqxmd.com/read/28258757/-frontal-fibrosing-alopecia-a-prospective-study-of-20%C3%A2-cases
#17
S Elloudi, S Gallouj, M Meziane, F-Z Mernissi, M Rimani
BACKGROUND: Frontal fibrosing alopecia (FFA) is a variant of lichen planopilaris predominantly affecting postmenopausal women. We report a series of 20 cases of FFA and describe the epidemiological, clinical, dermoscopic features and progress under treatment. PATIENTS AND METHODS: This was a prospective study conducted over a period of 16 months in patients seen at the dermatology department of the Hassan II University in Fez, Morocco. RESULTS: Mean patient age was 46 years...
February 28, 2017: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/28249244/hair-growth-promoting-effect-of-white-wax-and-policosanol-from-white-wax-on-the-mouse-model-of-testosterone-induced-hair-loss
#18
Zhan-di Wang, Ying Feng, Li-Yi Ma, Xian Li, Wei-Feng Ding, Xiao-Ming Chen
White wax (WW) has been traditionally used to treat hair loss in China. However there has been no reporter WW and its extract responsible for hair growth-promoting effect on androgenetic alopecia. In this paper, we examined the hair growth-promoting effects of WW and policosanol of white wax (WWP) on model animal of androgenetic alopecia and the potential target cell of WW and WWP. WW (1, 10 and 20%) and WWP (0.5, 1 and 2%) were applied topically to the backs of mice. Finasteride (2%) was applied topically as a positive control...
February 26, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28236431/catamenial-like-seizure-exacerbation-in-mice-with-targeted-ablation-of-extrasynaptic-%C3%AE-gaba-a-receptors-in-the-brain
#19
Bryan L Clossen, Doodipala Samba Reddy
Neurosteroids play a key role in catamenial epilepsy, a menstrual cycle-related seizure clustering in women with epilepsy. While neurosteroids act on all GABA-A receptor isoforms, they cause greater effects on extrasynaptic δGABA-A receptors that mediate tonic inhibition in the brain. Previously, we identified a potential GABA-A receptor mechanism for catamenial epilepsy. However, the precise functional role of extrasynaptic δGABA-A receptors in the pathophysiology of catamenial epilepsy remains unclear. In this study, we utilized mice lacking extrasynaptic δGABA-A receptors (δKO) to investigate whether reduction of tonic inhibition affects catamenial seizure susceptibility or intensity...
February 25, 2017: Journal of Neuroscience Research
https://www.readbyqxmd.com/read/28228662/risk-of-gynecomastia-and-breast-cancer-associated-with-the-use-of-5-alpha-reductase-inhibitors-for-benign-prostatic-hyperplasia
#20
Katrina Wilcox Hagberg, Hozefa A Divan, Shona C Fang, J Curtis Nickel, Susan S Jick
BACKGROUND: Clinical trial results suggest that 5-alpha reductase inhibitors (5ARIs) for the treatment of benign prostatic hyperplasia (BPH) may increase the risk of gynecomastia and male breast cancer, but epidemiological studies have been limited. PATIENTS AND METHODS: We conducted a cohort study with nested case-control analyses using the UK Clinical Practice Research Datalink. We identified men diagnosed with BPH who were free from Klinefelter syndrome, prostate, genital or urinary cancer, prostatectomy or orchiectomy, or evidence of gynecomastia or breast cancer...
2017: Clinical Epidemiology
keyword
keyword
111260
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"